patritumab

Patritumab is a humanized monoclonal antibody that targets the protein CD47. CD47 is a marker found on the surface of most cells in the body, including cancer cells. It helps these cells evade the immune system by interacting with the complement system and the scavenger receptor CD36. Patritumab is designed to bind to CD47 on the surface of cancer cells, preventing them from interacting with CD36 and allowing the immune system to recognize and attack the cancer cells.

The development of patritumab was driven by the need for more effective treatments for cancer, particularly for patients whose cancer has metastasized or recurred. Clinical trials have shown that patritumab can increase the effectiveness of other cancer treatments, such as chemotherapy and radiation therapy, by enhancing the immune system's ability to fight cancer cells.

Patritumab is typically administered intravenously and is often used in combination with other therapies. It is approved for use in certain types of cancer, including acute myeloid leukemia, chronic myeloid leukemia, and multiple myeloma. The most common side effects of patritumab are similar to those of other monoclonal antibodies, including infusion reactions, infusion-related reactions, and hypersensitivity reactions.

Patritumab is a promising treatment option for cancer patients, but like all medications, it has potential risks and benefits that should be carefully considered by healthcare providers and patients. Ongoing research is focused on expanding the use of patritumab to other types of cancer and improving its safety and efficacy.